SYX1097 / SynRx Therap - LARVOL DELTA

Clinic-ready Polθ inhibitor SYX1097 suppresses solid tumors in vivo (AACR 2024) - "SYX1097 also enhanced tumor cell sensitivity to Olaparib 5 to 15 times. It possesses remarkable pharmacokinetic properties in various species, with no hematological toxicity observed during the preclinical toxicity studies. SYX1097 is advancing towards IND filing in 2024.Collectively, SYX1097 is a promising small molecule that may be utilized as a single agent or in combination with PARPi for cancer treatment not only limited by HR deficiency."

Preclinical • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD